Compare DexCom, Inc. (DXCM) vs TotalEnergies SE (TTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs TotalEnergies SE — how do they compare? DexCom, Inc. trades at $78.55 (market cap $28.06B), while TotalEnergies SE trades at $79.2 (market cap $178.73B). The key difference: TotalEnergies SE is far larger — about 6.4× DexCom, Inc.'s market cap, and TotalEnergies SE pays a 5.25% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | TTE | |
|---|---|---|
Market Cap | $28.06B | $178.73B |
Sector | Health | Energy |
52-Week High | $89.53 | $93.60 |
52-Week Low | $54.84 | $57.39 |
Enterprise Value | $27.03B | $212.87B |
Dividend Yield | — | 5.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
TotalEnergies (TTE) trades at $80.91, down 0.37% on the day, with strong technical momentum indicated by a bullish moving average signal. The company maintains solid fundamentals with a P/E of 11.92 and ROE of 12.55%, though revenue has declined from $263.3B in 2022 to $182.3B in 2025. Recent news highlights strategic divestments and new energy project developments, while analyst consensus remains strongly positive with 19 buy ratings.
TTE presents a compelling value opportunity with attractive valuation metrics and consistent dividend payments. However, investors face risks from declining revenue trends, geopolitical exposure in oil-producing regions, and regulatory pressures on emissions. The stock's current technical strength and positive analyst sentiment suggest potential upside, but requires monitoring of operational execution and energy market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About TotalEnergies SE
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.
Read more on TTE →
